Three-Dimensional Echocardiography As A Predictor Of Positive Response To Cardiac Resynchronisation Therapy

To assess patients with three-dimensional echocardiography before cardiac resynchronisation therapy device implantation to predict the responders, and to determine the response 3 months post-intervention.

The descriptive study was conducted at Kafrelsheikh University Hospital, Egypt, from January 2020 to March 2022, and comprised patients of either gender who underwent cardiac resynchronisation therapy device implantation. The patients were assessed clinically and with three-dimensional echocardiography using 16-segment systolic dyssynchrony index asthe main parameter compared at baseline and 3 months after implantation. The patients were classified as non-responders, clinical responders, and clinical and echocardiographic responders. Data was analysed using SPSS 23.

Of the 40 patients, 23(57.5%) were males and 17(42.5%) were females. The overall mean age was 57.43±10.47 years, mean body weight was 81.30±11.33kg, mean height was 171.15±10.56cm), and mean body surface area was 1.93±0.17m2. Of the total, 14(35%) patients were hypertensive, 10(25%) diabetic, 15(37.5%) ischaemic and 2(5%) patients had atrial fibrillation. There were 8(20%) non-responders, 8(20%) clinical responders, and 24(60%) clinical and echocardiographic responders to therapy. Mean systolic dyssynchrony index at baseline was a positive highly significant predictor of post-therapy response (p<0.01). A positive highly significant correlation was also found between post-therapy response and end-systolic volume, three-dimensional ejection fraction, New York Heart Association class and QRS width (p<0.01).

Three-dimensional 16-segmentsystolic dyssynchrony index wasfound to be a significantly effective tool to predict response to cardiac resynchronisation therapy device implantation.